Patients with post-IPI therapy N = 111

Demographic characteristics measured at index

Age, mean (SD)

57.1 (13.1)

Male, %

64.9

Medicare beneficiary, %

26.1

Insurance plan type, %

Comprehensive

5.4

EPO

0.9

HMO

4.5

POS (includes w/capitation)

5.4

PPO

67.6

Other (basic/major medical, CHDP, HDHP)

9.9

Unknown/missing

6.3

Clinical characteristics measured at index and during baseline period

Baseline National Cancer Institute comorbidity index, mean (SD)

0.4 (0.8)

Baseline unique number of National Drug Codes, mean (SD)

11.9 (7.5)

Baseline selected comorbid conditions with >5% prevalence, %

Brain/leptomeningeal metastasis

35.1

Hypertension

33.3

Chronic liver disease

14.4

Myocardial infarction/coronary artery disease

11.7

Diabetes

9.9

Cerebrovascular disease

8.1

Renal disease

7.2

Autoimmune disorders

6.3

Congestive heart failure

5.4

Ocular melanoma

5.4

Diagnosing physician specialty, %

Oncologist/hematologist

26.1

General surgeon

16.2

Dermatologist

0.9

Primary care provider

9.9

Radiologist/nuclear medicine

17.1

Other specialist

10.8

Other provider

0.9

Facility

9.9

Unknown

8.1